Press releases
Press releases dating back to 2009 are available below. Search them by keyword or browse by year/business category. Press releases for our local operating companies can be viewed on our country websites.
-
GSK presents new results showing low rates of organ damage with long term use of Benlysta
GSK today announced results from two new analyses showing low rates of organ damage progression in patients with active systemic lupus erythematosus (SLE) treated with Benlysta ...
Read more -
GSK announces changes to Vaccines and Global Manufacturing & Supply leadership
Luc Debruyne, President, Vaccines, is to leave GSK at the end of the year.
Read more -
GSK completes Consumer Healthcare buyout
GSK has completed the buyout of Novartis’ 36.5% stake in its Consumer Healthcare Joint Venture for $13 billion (£9.3 billion*).
Read more -
GSK submits regulatory application in Japan for once-daily single inhaler triple therapy FF/UMEC/VI for patients with COPD
GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the submission of a regulatory application to the Japanese Ministry of Health, Labour and W...
Read more -
ViiV Healthcare receives EU marketing authorisation for Juluca (dolutegravir/rilpivirine), the first 2-drug regimen, once-daily, single-pill for the treatment of HIV
Juluca maintains viral suppression with two drugs in the smallest single pill regimen
Read more -
GSK receives US approval of Arnuity Ellipta for use in children from 5 years old who suffer from asthma
GSK today announced it has received approval from the US Food and Drug Administration (FDA) for the use of Arnuity Ellipta (fluticasone furoate) a once-daily inhaled corticoster...
Read more -
Nucala (mepolizumab) study reports long-term safety data, consistent exacerbation reduction and improved asthma control
New study showed one third of patients had no exacerbations on long-term treatment with Nucala.
Read more -
GSK’s industry-leading respiratory research and scientific innovation showcased at ATS conference
GlaxoSmithKline plc (GSK) will present extensive data from across its respiratory portfolio, pipeline and early phase research programmes at the American Thoracic Society (ATS) ...
Read more -
Simon Dingemans, Chief Financial Officer, to retire from GSK
Simon Dingemans, Chief Financial Officer (CFO), GSK, has informed the Board of his intention to retire from the Company and to step down from the Board in May 2019.
Read more -
GSK delivers Q1 sales of £7.2 billion, -2% AER, +4% CER
Total EPS 11.2p, -48% AER, -33% CER; Adjusted EPS 24.6p, -2% AER, +11% CER
Read more -
Once-daily Trelegy Ellipta gains expanded indication in the US for the treatment of patients with COPD
Expanded indication approved for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol ‘FF/UMEC/VI’)
Read more -
Landmark IMPACT study published in NEJM shows significant benefits of Trelegy Ellipta for patients with COPD
Once-daily single inhaler triple therapy superior to Relvar/Breo Ellipta and Anoro Ellipta across multiple endpoints including exacerbations, lung function and quality of life.
Read more -
GSK appoints Kevin Sin as new SVP and Head of Worldwide Business Development for R&D
Kevin Sin appointed as Senior Vice President and Head of Worldwide Business Development for Pharmaceuticals Research & Development.
Read more -
GSK signs strategic agreement to transfer rare disease gene therapy portfolio to Orchard Therapeutics
Agreement strengthens Orchard’s position as a global leader in gene therapy for rare diseases. GSK takes 19.9% equity stake in Orchard and seat on board.
Read more -
GSK reaches agreement with Novartis to acquire full ownership of Consumer Healthcare Business
GSK reaches agreement with Novartis to acquire full ownership of Consumer Healthcare Business
Read more -
ViiV Healthcare gains CHMP positive opinion for Juluca (dolutegravir/rilpivirine) in Europe
ViiV Healthcare today announced that the European Committee for Medicinal Products for Human Use has issued a Positive Opinion recommending marketing authorisation for Juluca.
Read more -
Shingrix approved in Europe and Japan for the prevention of shingles in adults aged 50 and over
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the European Commission has approved Shingrix for the prevention of shingles (herpes zoster) and post-herpetic neuralgia...
Read more -
GSK update regarding Pfizer Inc. Consumer Healthcare
GlaxoSmithKline plc (LSE/NYSE: GSK) today confirms it has withdrawn from the process relating to Pfizer’s Consumer Healthcare business.
Read more -
GSK starts phase III study of Benlysta and rituximab combination in systemic lupus erythematosus
GSK today announced the start of a phase III study investigating Benlysta (belimumab) in combination with rituximab in adult patients with systemic lupus erythematosus (SLE).
Read more -
GSK announces positive EU approval for labelling update to Relvar Ellipta in patients with asthma
GlaxoSmithKline plc (LSE/NYSE:GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the European Commission has approved a label update for the use of once-daily Relvar El...
Read more
Find out more about us
-
About us
We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
-
Products
We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare
-
Research and development
Science can improve health and well-being in so many ways, from the development of everyday convenience healthcare products through to life-saving medicines and vaccines.
-
Behind the science
Explore innovations in medicines, vaccines and consumer healthcare from inside and outside our labs.
